metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Enfermedad por reflujo gastroesofágico refractaria a esomeprazol
Información de la revista
Vol. 28. Núm. 2.
Páginas 65-67 (febrero 2005)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 28. Núm. 2.
Páginas 65-67 (febrero 2005)
Observaciones clínicas
Acceso a texto completo
Enfermedad por reflujo gastroesofágico refractaria a esomeprazol
Gastroesophageal reflux disease Refractory to esomeprazole
Visitas
9525
M.J. Velasco
Autor para correspondencia
manueljosev@hotmail.com

Correspondencia: Dr. M.J. Velasco Rodríguez. Servicio de Medicina Digestiva. Hospital Universitari La Fe. Avda. Campanar, 21. 46009 Valencia. España.
, V. Ortiz, J. Ponce
Servicio de Medicina Digestiva. Hospital Universitari La Fe. Valencia. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

La resistencia al tratamiento con inhibidores de la bomba de protones (IBP) en la enfermedad por reflujo gastroesofágico (ERGE), descrita en pacientes tratados con omeprazol, puede explicar algunos casos excepcionales de fracaso terapéutico y la pertinencia de indicar tratamiento quirúrgico. La prueba objetiva de resistencia a IBP se obtiene con pHmetría intragástrica de 24 h, realizada en el curso del tratamiento, al encontrar un pH gástrico inferior a 4 más del 50% del tiempo de registro. Se presenta un paciente con ERGE no erosiva con fracaso clínico al tratamiento con omeprazol y resistencia probada a esomeprazol que, en nuestro conocimiento, sólo se ha documentado en pacientes con esófago de Barrett.

Resistance to proton pump inhibitors (PPI) in gastroesophageal reflux disease (GERD), which has been described in patients treated with omeprazole, could explain some exceptional cases of treatment failure and the need for surgery. The objective test of resistance to PPI is obtained with 24-hour intragastric pH-metry performed during treatment. A gastric pH of less than 4 for more than 50% of recording time indicates resistance. We present a patient with non-erosive GERD and treatment failure to omeprazole and proven resistance to esomeprazole which, to our knowledge, has only been reported in patients with Barrett’s esophagus

El Texto completo está disponible en PDF
Bibliografía
[1.]
R. Fass, J.J. Ofman.
Gastroesophageal reflux disease-should we adopt a new conceptual framework?.
Am J Gastroent, 97 (2002), pp. 1901-1909
[2.]
J.G. Hatlebakk, P.O. Katz, D. Castell.
Medical therapy. Management of the refractory patient.
Gastroenterol Clin North Am, 28 (1999), pp. 847-860
[3.]
J. Vaquer, J. Ponce, O. Vegazo, A. Palacios, S. Sofos, J. Zapardiel, et al.
Enfermedad por reflujo gastroesofágico (ERGE) en España. Prevalencia, factores de riesgo y calidad de vida.
Gastroenterol Hepatol, 27 (2004), pp. 179
[4.]
K. Rohss, G. Hasselgren, H. Hedenstrom.
Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease.
Dig Dis Sci, 47 (2002), pp. 954-958
[5.]
P. Miner Jr, P.O. Katz, Y. Chen, M. Sostek.
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study.
Am J Gastroenterol, 98 (2003), pp. 2616-2620
[6.]
K. Rohss, C. Wilder-Smith, E. Naucler, L. Jansson.
Esomeprazole 20 mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers.
Clinical Drug Investigation, 24 (2004), pp. 1-7
[7.]
R.W. Yeh, L.B. Gerson, G. Triadafilopoulos.
Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett’s esophagus.
Dis Esophagus, 16 (2003), pp. 193-198
[8.]
J. Isolauri, M. Luostarinen, E. Isolauri, P. Reinikainen, M. Viljakka, O. Keyrilainen.
Natural course of gastroesophageal reflux disease: a follow-up of 60 patients.
Am J Gastroent, 92 (1997), pp. 37-41
[9.]
L. Leite, R. Just, D. Castell, P. Lagerström.
Control of gastric acid with high dose H2-receptor antagonists after omeprazole failure: report of two cases.
Am J Gastroent, 90 (1995), pp. 1874-1877
[10.]
S. Xue, P.O. Katz, P. Banerjee, R. Tutuian, D.O. Castell.
Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
Aliment Pharmacol Ther, 15 (2001), pp. 1351-1356
[11.]
W.K. Fackler, T.M. Ours, M.F. Vaezi, J.E. Richter.
Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough.
Gastroenterology, 122 (2002), pp. 625-632
[12.]
P.J. Kahrilas, G.W. Falk, D.A. Johnson, C. Schmitt, D.W. Collins, J. Whipple, et al.
Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomised controlled trial.
Aliment Pharmacol Ther, 14 (2000), pp. 1249-1258
[13.]
J. Richter, P. Kahrilas, J. Johanson, P. Maton, J.R. Breiter, C. Hwang, et al.
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
Am J Gastroenterol, 96 (2001), pp. 656-665
[14.]
S.J. Edwards, T. Lind, L. Lundell.
Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.
Aliment Pharmacol Ther, 15 (2001), pp. 1729-1736
[15.]
D. Castell, P. Kahrilas, J. Richter, N.B. Vakil, D.A. Johnson, S. Zuckerman, et al.
Esomeprazole 40 mg compared with lansoprazole 30 mg on the treatment of erosive esophagitis.
Am J Gastroenterol, 97 (2002), pp. 575-583
[16.]
J. Labenz, N. Keeling, S. Eklund.
A comparison of esomeprazole 40 mg once-daily and pantoprazole 40 mg once-daily for heling of reflux oesophagitis.
Póster presentado en el 11th UEGW, (Noviembre 2003),
[17.]
P. Lindberg, D. Keeling, J. Fryklund, T. Andersson, P. Lundborg, E. Carlsson.
Review article: esomeprazole- enhanced bio-availability, specifity for the proton pump and inhibition of acid secretion.
Aliment Pharmacol Ther, 17 (2003), pp. 481-488
[18.]
O. Philip.
Katz Lessons learned from intragastric pH monitoring.
J Clin Gastroenterol, 33 (2001), pp. 107-113
[19.]
B. Kuo, D. Castell.
Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls.
Am J Gastroent, 91 (1996), pp. 1532-1538
[20.]
P.O. Katz, C. Anderson, R. Khoury, D.O. Castell.
Gastro-esophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
Aliment Pharmacol Ther, 12 (1999), pp. 1231-1234
[21.]
U.C. Nzeako, J.A. Murray.
An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
Aliment Pharmacol Ther, 16 (2002), pp. 1309-1316
Copyright © 2005. Elsevier España S.L.. Todos los derechos reservados
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos